Yahui Liao

NAT-A exhibits anti-tumor activity against acquired epidermal growth factor receptor- tyrosine kinase inhibitor-resistant non-small cell lung cancer via inhibiting the β-catenin/PKM2 axis

Hyperactivation of the Wnt/β-catenin pathway is a key driver of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistance in non-small cell lung cancer (NSCLC), with pyruvate kinase M2 (PKM2) serving as a critical transcriptional coactivator of β -catenin....